DK1425038T4 - Svækkede bakterier, der er anvendelige i vacciner - Google Patents

Svækkede bakterier, der er anvendelige i vacciner

Info

Publication number
DK1425038T4
DK1425038T4 DK02755363.5T DK02755363T DK1425038T4 DK 1425038 T4 DK1425038 T4 DK 1425038T4 DK 02755363 T DK02755363 T DK 02755363T DK 1425038 T4 DK1425038 T4 DK 1425038T4
Authority
DK
Denmark
Prior art keywords
attenuated
vaccines
bacteria
attenuated bacteria
enterotoxins
Prior art date
Application number
DK02755363.5T
Other languages
English (en)
Other versions
DK1425038T3 (da
Inventor
Arthur K Turner
Jonathan C Stephens
Juliet C Beavis
Michael J Darsley
Judith Greenwood
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1425038(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of DK1425038T3 publication Critical patent/DK1425038T3/da
Publication of DK1425038T4 publication Critical patent/DK1425038T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02755363.5T 2001-09-11 2002-09-11 Svækkede bakterier, der er anvendelige i vacciner DK1425038T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines
PCT/GB2002/004164 WO2003022307A1 (en) 2001-09-11 2002-09-11 Attenuated bacteria useful in vaccines

Publications (2)

Publication Number Publication Date
DK1425038T3 DK1425038T3 (da) 2006-03-27
DK1425038T4 true DK1425038T4 (da) 2010-12-13

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02755363.5T DK1425038T4 (da) 2001-09-11 2002-09-11 Svækkede bakterier, der er anvendelige i vacciner
DK02755355T DK1425037T3 (da) 2001-09-11 2002-09-11 Bakteriel vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02755355T DK1425037T3 (da) 2001-09-11 2002-09-11 Bakteriel vaccine

Country Status (10)

Country Link
US (4) US7951361B2 (da)
EP (2) EP1425038B2 (da)
AT (2) ATE308992T1 (da)
AU (2) AU2002321652B2 (da)
CA (2) CA2459586A1 (da)
DE (2) DE60207277T2 (da)
DK (2) DK1425038T4 (da)
ES (2) ES2256514T3 (da)
GB (1) GB0121998D0 (da)
WO (2) WO2003022307A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7468269B2 (en) * 2003-02-26 2008-12-23 University Of Massachusetts Reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
US7759106B2 (en) 2004-05-19 2010-07-20 The United States Of America As Represented By The Secretary Of The Army Construction of live attenuated Shigella vaccine strains that express CFA/I antigens (CfaB and CfaE) and the B subunit of heat-labile enterotoxin (LTB) from enterotoxigenic E. coli
US9328150B2 (en) 2005-01-11 2016-05-03 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits
CA2592444C (en) 2005-01-11 2015-04-07 Stephen J. Savarino Adhesin as immunogen against escherichia coli
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2007089205A1 (en) * 2006-02-01 2007-08-09 Sbl Vaccin Ab Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria
KR20100040847A (ko) * 2007-07-02 2010-04-21 크루셀 스웨덴 아베 장독소생산 Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉ 세균의 콜로니화 인자(ＣＦ) 항원의 발현을 위한 혼성 오페론
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
ES2558454T3 (es) * 2011-09-12 2016-02-04 Scandinavian Biopharma Holding Ab Método para aumentar la presentación de antígeno CS6 de ETEC sobre la superficie celular y productos que pueden obtenerse del mismo
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
US9925254B2 (en) 2014-11-05 2018-03-27 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
WO2019195437A1 (en) * 2018-04-03 2019-10-10 University Of Maryland, Baltimore Enhanced shigella-enterotoxigenic e. coli multi-valent vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
CA2099841C (en) 1991-03-05 2003-02-25 Ian G. Charles Expression of recombinant proteins in attenuated bacteria
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
AU5762299A (en) 1999-09-15 2001-04-17 Mogam Biotechnology Research Institute Novel detoxified mutants of escherichia coli heat-labile enterotoxin
MXPA02010407A (es) * 2000-04-20 2003-05-23 Univ Maryland Aislamiento y caracterizacion del operante csa (etec-cs4-pili) y metodos para su uso.
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
US9327019B2 (en) * 2009-06-30 2016-05-03 Stc.Unm Attenuated enterohemorrhagic E. coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
US8318148B2 (en) 2012-11-27
US20040253710A1 (en) 2004-12-16
US20110189225A1 (en) 2011-08-04
WO2003022306A3 (en) 2003-06-26
DE60207277T2 (de) 2006-08-03
AU2002321644B2 (en) 2008-03-13
US7943122B2 (en) 2011-05-17
DK1425038T3 (da) 2006-03-27
ES2256515T3 (es) 2006-07-16
ES2256515T5 (es) 2011-02-25
DE60207278T2 (de) 2006-08-10
EP1425037B1 (en) 2005-11-09
US20050054075A1 (en) 2005-03-10
AU2002321652B2 (en) 2008-04-10
EP1425037A2 (en) 2004-06-09
EP1425038A1 (en) 2004-06-09
ATE308991T1 (de) 2005-11-15
DE60207277D1 (de) 2005-12-15
DE60207278D1 (de) 2005-12-15
WO2003022306A2 (en) 2003-03-20
WO2003022307A1 (en) 2003-03-20
EP1425038B2 (en) 2010-09-01
DE60207278T3 (de) 2011-05-05
CA2460025A1 (en) 2003-03-20
DK1425037T3 (da) 2006-03-27
CA2459586A1 (en) 2003-03-20
US7951361B2 (en) 2011-05-31
ES2256514T3 (es) 2006-07-16
ATE308992T1 (de) 2005-11-15
EP1425038B1 (en) 2005-11-09
GB0121998D0 (en) 2001-10-31
US20110200638A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
DK1425038T4 (da) Svækkede bakterier, der er anvendelige i vacciner
NO20015073L (no) Vaksiner
HUP0203056A1 (hu) Vakcinakészítmény
MA29459B1 (fr) Vaccins
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
PL1618128T3 (pl) Szczepionka przeciwko gruźlicy o ulepszonej skuteczności
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
NO20025329L (no) Virulensgener, proteiner og deres anvendelse
NO20062469L (no) Streptococcus phocae vaksine
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
ATE442857T1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
RU2002122063A (ru) Штам бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины
DE602004031127D1 (de) Attenuierte bakterielle lebendvakzine
WO2004083390A3 (en) Virulent systemic feline calicivirus
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
RU2003122317A (ru) Средство, повышающее иммуногенные свойства столбнячного анатоксина
CY1117291T1 (el) Εμβολιο κατα του ροταϊου
RU99117155A (ru) Штамм бактерий pseudomonas aeruginosa 5292, используемый для изготовления вакцины против псевдомоноза пушных зверей